JP6422986B2 - 化合物 - Google Patents
化合物 Download PDFInfo
- Publication number
- JP6422986B2 JP6422986B2 JP2016549028A JP2016549028A JP6422986B2 JP 6422986 B2 JP6422986 B2 JP 6422986B2 JP 2016549028 A JP2016549028 A JP 2016549028A JP 2016549028 A JP2016549028 A JP 2016549028A JP 6422986 B2 JP6422986 B2 JP 6422986B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- pharmaceutically acceptable
- methyl
- lcms
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCOc1nc(Nc(cn[n]2[C@@](CCN(C3)C4C*C4)[C@@]3F)c2Cl)nc2c1cc[n]2 Chemical compound CCOc1nc(Nc(cn[n]2[C@@](CCN(C3)C4C*C4)[C@@]3F)c2Cl)nc2c1cc[n]2 0.000 description 12
- WYQCVYWGTNXXGO-DQTVNRMBSA-N C/C=C/C(/[N+]([O-])=O)=C\N(C)C(CCOC1)C1F Chemical compound C/C=C/C(/[N+]([O-])=O)=C\N(C)C(CCOC1)C1F WYQCVYWGTNXXGO-DQTVNRMBSA-N 0.000 description 1
- PXNPGAPJCXDNLK-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1(F)F)CC1[n]1ncc(N)c1C)=O Chemical compound CC(C)(C)OC(N(CCC1(F)F)CC1[n]1ncc(N)c1C)=O PXNPGAPJCXDNLK-UHFFFAOYSA-N 0.000 description 1
- NXMTVLPMEXUIPC-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1=O)CC1[n]1ncc([N+]([O-])=O)c1)=O Chemical compound CC(C)(C)OC(N(CCC1=O)CC1[n]1ncc([N+]([O-])=O)c1)=O NXMTVLPMEXUIPC-UHFFFAOYSA-N 0.000 description 1
- XJOMQNRXMYCVAH-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1[n]2ncc([N+]([O-])=O)c2)CC1F)=O Chemical compound CC(C)(C)OC(N(CCC1[n]2ncc([N+]([O-])=O)c2)CC1F)=O XJOMQNRXMYCVAH-UHFFFAOYSA-N 0.000 description 1
- FERPMNAOMKPJET-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1[n]2ncc([N+]([O-])=O)c2C)CC1F)=O Chemical compound CC(C)(C)OC(N(CCC1[n]2ncc([N+]([O-])=O)c2C)CC1F)=O FERPMNAOMKPJET-UHFFFAOYSA-N 0.000 description 1
- XLSAQENNLCJRAX-UHFFFAOYSA-N CC(C1)(CC1O)[n]1ncc(N)c1C Chemical compound CC(C1)(CC1O)[n]1ncc(N)c1C XLSAQENNLCJRAX-UHFFFAOYSA-N 0.000 description 1
- RMUMFNPDDLMEPT-UHFFFAOYSA-N CC(C1)(CC1OCc1ccccc1)O Chemical compound CC(C1)(CC1OCc1ccccc1)O RMUMFNPDDLMEPT-UHFFFAOYSA-N 0.000 description 1
- OWKKAOIAXKWVJW-UHFFFAOYSA-N CC(C1)(CC1OCc1ccccc1)[n]1ncc([N+]([O-])=O)c1 Chemical compound CC(C1)(CC1OCc1ccccc1)[n]1ncc([N+]([O-])=O)c1 OWKKAOIAXKWVJW-UHFFFAOYSA-N 0.000 description 1
- YHFAIMLAXQOUIZ-UHFFFAOYSA-N CC(CCC1)(C1[n]1ncc([N+]([O-])=O)c1C)O Chemical compound CC(CCC1)(C1[n]1ncc([N+]([O-])=O)c1C)O YHFAIMLAXQOUIZ-UHFFFAOYSA-N 0.000 description 1
- ICYDYPYAWMFAOT-ZLZJIPBDSA-N CCC[C@@H]([C@@H](CNC1COC1)F)[N-](C1Cl)([NH+]=CC1Nc1nc([nH]cc2)c2c(OCC)n1)#C Chemical compound CCC[C@@H]([C@@H](CNC1COC1)F)[N-](C1Cl)([NH+]=CC1Nc1nc([nH]cc2)c2c(OCC)n1)#C ICYDYPYAWMFAOT-ZLZJIPBDSA-N 0.000 description 1
- SRZCNFCBCVDIHX-UHFFFAOYSA-N CCOC(C(C)(C)[n]1ncc([N+]([O-])=O)c1)=O Chemical compound CCOC(C(C)(C)[n]1ncc([N+]([O-])=O)c1)=O SRZCNFCBCVDIHX-UHFFFAOYSA-N 0.000 description 1
- JXVRMNDCBILRET-UHFFFAOYSA-N CCOC(CN(C)C(C)COC)N1NCC(Nc2nc(OCC)c(cc[nH]3)c3n2)=C1Cl Chemical compound CCOC(CN(C)C(C)COC)N1NCC(Nc2nc(OCC)c(cc[nH]3)c3n2)=C1Cl JXVRMNDCBILRET-UHFFFAOYSA-N 0.000 description 1
- MPLFKMGGAIIQGV-PKNBQFBNSA-N CCOC1=C(C=CN2)C2=NC(N/C(/CN)=C(\C)/N(CCF)N)N1 Chemical compound CCOC1=C(C=CN2)C2=NC(N/C(/CN)=C(\C)/N(CCF)N)N1 MPLFKMGGAIIQGV-PKNBQFBNSA-N 0.000 description 1
- GBGNKLZXYKEGPJ-SUAWAIIZSA-N CCOC1NC(Nc(cn[n]2[C@@H](CCN(C3)C4COC4)[C@H]3F)c2Cl)=Nc2c1cc[nH]2 Chemical compound CCOC1NC(Nc(cn[n]2[C@@H](CCN(C3)C4COC4)[C@H]3F)c2Cl)=Nc2c1cc[nH]2 GBGNKLZXYKEGPJ-SUAWAIIZSA-N 0.000 description 1
- AIAXKVXVWXZBFW-UHFFFAOYSA-N CCOCCN(C)C(CC1)CC1[n]1ncc([N+]([O-])=O)c1Cl Chemical compound CCOCCN(C)C(CC1)CC1[n]1ncc([N+]([O-])=O)c1Cl AIAXKVXVWXZBFW-UHFFFAOYSA-N 0.000 description 1
- YTEPHMOFURICDX-UKRRQHHQSA-N CCOc1c(cc[nH]2)c2nc(Nc(cn[n]2[C@H](CCN(C3)C4COC4)[C@@H]3F)c2Cl)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(Nc(cn[n]2[C@H](CCN(C3)C4COC4)[C@@H]3F)c2Cl)n1 YTEPHMOFURICDX-UKRRQHHQSA-N 0.000 description 1
- HWDIZXFYSRFTSA-UHFFFAOYSA-N CCOc1c(cc[nH]2)c2nc(Nc2c(C)[n](C(CCN(C3)C4COC4)C3(F)F)nc2)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(Nc2c(C)[n](C(CCN(C3)C4COC4)C3(F)F)nc2)n1 HWDIZXFYSRFTSA-UHFFFAOYSA-N 0.000 description 1
- PUJBOTVHHWCBOX-OAXRTPEGSA-N CCOc1c(cc[nH]2)c2nc(Nc2c(C)[n](C(CCN(C3COC3)C3C[C@H](C)C(C)=C)C3F)nc2)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(Nc2c(C)[n](C(CCN(C3COC3)C3C[C@H](C)C(C)=C)C3F)nc2)n1 PUJBOTVHHWCBOX-OAXRTPEGSA-N 0.000 description 1
- NGJACAHAGMHHQT-GFCCVEGCSA-N COC([C@@H]1N(Cc2ccccc2)CCC1)=O Chemical compound COC([C@@H]1N(Cc2ccccc2)CCC1)=O NGJACAHAGMHHQT-GFCCVEGCSA-N 0.000 description 1
- FEUMEIPWCKWJPC-UHFFFAOYSA-N COc([n](C1CCOCC1)nc1)c1N Chemical compound COc([n](C1CCOCC1)nc1)c1N FEUMEIPWCKWJPC-UHFFFAOYSA-N 0.000 description 1
- KKFBDQNGSHITHV-SECBINFHSA-N C[C@H]1N(CC[n]2ncc([N+]([O-])=O)c2C)CCOC1 Chemical compound C[C@H]1N(CC[n]2ncc([N+]([O-])=O)c2C)CCOC1 KKFBDQNGSHITHV-SECBINFHSA-N 0.000 description 1
- CLIAXYPZANDZOI-IUCAKERBSA-N Cc([n]([C@@H](CCN(C)C1)[C@H]1F)nc1)c1[N+]([O-])=O Chemical compound Cc([n]([C@@H](CCN(C)C1)[C@H]1F)nc1)c1[N+]([O-])=O CLIAXYPZANDZOI-IUCAKERBSA-N 0.000 description 1
- MTSYGZQPQUPHNN-UHFFFAOYSA-N NNC1CC(C2)C2C1 Chemical compound NNC1CC(C2)C2C1 MTSYGZQPQUPHNN-UHFFFAOYSA-N 0.000 description 1
- RIOZJRQBPYVKAX-JAMMHHFISA-N Nc(cn[n]1C(C[C@@H](C2)F)CN2C2COC2)c1Cl Chemical compound Nc(cn[n]1C(C[C@@H](C2)F)CN2C2COC2)c1Cl RIOZJRQBPYVKAX-JAMMHHFISA-N 0.000 description 1
- RQNUOFAKLTYGLH-PHDIDXHHSA-N [O-][N+](c(cn[n]1[C@H](CCNC2)[C@@H]2F)c1Cl)=O Chemical compound [O-][N+](c(cn[n]1[C@H](CCNC2)[C@@H]2F)c1Cl)=O RQNUOFAKLTYGLH-PHDIDXHHSA-N 0.000 description 1
- XYXJSXYKDKOEBW-UHFFFAOYSA-N [O-][N+](c1c[n](C(C2)CC22OCCO2)nc1)=O Chemical compound [O-][N+](c1c[n](C(C2)CC22OCCO2)nc1)=O XYXJSXYKDKOEBW-UHFFFAOYSA-N 0.000 description 1
- KDJIYPXAVQGDRT-UHFFFAOYSA-N [O-][N+](c1c[n](C(CC(CC2)=O)C2(F)F)nc1)=O Chemical compound [O-][N+](c1c[n](C(CC(CC2)=O)C2(F)F)nc1)=O KDJIYPXAVQGDRT-UHFFFAOYSA-N 0.000 description 1
- JKBQLGDMVDOSGQ-UHFFFAOYSA-N [O-][N+](c1c[n](C(CC(CC2)N3CCOCC3)C2(F)F)nc1)=O Chemical compound [O-][N+](c1c[n](C(CC(CC2)N3CCOCC3)C2(F)F)nc1)=O JKBQLGDMVDOSGQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000139 | 2014-01-29 | ||
| CNPCT/CN2014/000139 | 2014-01-29 | ||
| PCT/CN2015/000055 WO2015113452A1 (en) | 2014-01-29 | 2015-01-28 | Compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504631A JP2017504631A (ja) | 2017-02-09 |
| JP2017504631A5 JP2017504631A5 (enExample) | 2018-05-10 |
| JP6422986B2 true JP6422986B2 (ja) | 2018-11-14 |
Family
ID=53756224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549028A Expired - Fee Related JP6422986B2 (ja) | 2014-01-29 | 2015-01-28 | 化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10087186B2 (enExample) |
| EP (1) | EP3099695B1 (enExample) |
| JP (1) | JP6422986B2 (enExample) |
| KR (1) | KR20160106622A (enExample) |
| CN (1) | CN105940004B (enExample) |
| AU (2) | AU2015210593A1 (enExample) |
| CA (1) | CA2937431A1 (enExample) |
| CL (1) | CL2016001895A1 (enExample) |
| CR (1) | CR20160348A (enExample) |
| DO (2) | DOP2016000195A (enExample) |
| EA (1) | EA029774B1 (enExample) |
| ES (1) | ES2802174T3 (enExample) |
| IL (1) | IL246579B (enExample) |
| MA (1) | MA39219B1 (enExample) |
| MX (1) | MX367370B (enExample) |
| PE (1) | PE20161443A1 (enExample) |
| PH (1) | PH12016501307A1 (enExample) |
| SG (1) | SG11201605342UA (enExample) |
| UA (1) | UA118369C2 (enExample) |
| WO (1) | WO2015113452A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10339791B2 (en) | 2007-06-12 | 2019-07-02 | Icontrol Networks, Inc. | Security network integrated with premise security system |
| SG11201605342UA (en) | 2014-01-29 | 2016-08-30 | Glaxosmithkline Ip Dev Ltd | Compounds |
| RU2016134751A (ru) | 2014-01-29 | 2018-03-02 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
| CN105153131B (zh) * | 2015-09-21 | 2017-10-17 | 马彦丽 | 一种在护理上治疗人神经胶质瘤的药物组合物 |
| CN105348270B (zh) * | 2015-11-09 | 2018-01-09 | 吕显艳 | 一种防治牙体牙髓感染的药物组合物 |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| CN108934162A (zh) | 2015-12-16 | 2018-12-04 | 南方研究所 | 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法 |
| CN105418616B (zh) * | 2015-12-26 | 2018-01-12 | 山东大学 | 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用 |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| PT3472153T (pt) | 2016-06-16 | 2021-12-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos |
| EP3573956A4 (en) * | 2017-01-25 | 2020-08-12 | GlaxoSmithKline Intellectual Property Management Limited | COMPOUNDS |
| EP3587422A4 (en) * | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE |
| FI3604304T3 (fi) | 2017-03-23 | 2022-12-15 | Pyrrolopyridiinijohdannaisyhdiste, menetelmä sen valmistamiseksi ja sitä vaikuttavana ainesosana sisältävä farmaseuttinen koostumus proteiinikinaasiin liittyvien tautien ehkäisemiseksi tai hoitamiseksi | |
| JP7230053B2 (ja) * | 2017-12-05 | 2023-02-28 | オスコテック インコーポレイテッド | Ｌｒｒｋ２阻害剤としてのピロロ（ピラゾロ）ピリミジン誘導体 |
| CN108715834B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种富含cd41+、cd81+微囊的血小板裂解液制备方法 |
| WO2020036437A1 (ko) * | 2018-08-16 | 2020-02-20 | 재단법인 대구경북첨단의료산업진흥재단 | 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| JP7447098B2 (ja) * | 2018-09-25 | 2024-03-11 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | アミノピリミジン化合物 |
| EP3915985A4 (en) | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES |
| CZ308800B6 (cs) | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
| AU2021371136A1 (en) | 2020-10-29 | 2023-05-11 | Merck Sharp & Dohme Llc | N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| AU2021371697B2 (en) * | 2020-10-29 | 2024-10-24 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| WO2023073013A1 (en) | 2021-10-27 | 2023-05-04 | H. Lundbeck A/S | Lrrk2 inhibitors |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| US11958865B1 (en) | 2022-09-15 | 2024-04-16 | H. Lundbeck A/S | Leucine-rich repeat kinase 2 (LRRK2) inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004274403A1 (en) | 2003-09-03 | 2005-03-31 | Aventis Pharmaceuticals Inc. | 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006045392A2 (en) | 2004-10-21 | 2006-05-04 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| JP2009511527A (ja) | 2005-10-13 | 2009-03-19 | グラクソ グループ リミテッド | Ｓｙｋ阻害物質としてのピロロピリミジン誘導体 |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US20090325964A1 (en) | 2008-05-23 | 2009-12-31 | Wyeth | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| ES2512727T3 (es) * | 2009-09-29 | 2014-10-24 | Glaxo Group Limited | Nuevos compuestos |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| KR101566091B1 (ko) * | 2010-11-10 | 2015-11-04 | 에프. 호프만-라 로슈 아게 | Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체 |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| AU2012244550C1 (en) | 2011-04-21 | 2017-06-22 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
| MD20140023A2 (ro) | 2011-09-22 | 2014-06-30 | Pfizer Inc. | Derivaţi de pirolpirimidină şi purină |
| WO2013079496A1 (en) | 2011-11-30 | 2013-06-06 | F. Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
| GB201204985D0 (en) * | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| WO2013164323A1 (en) | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| CN104271569B (zh) | 2012-05-03 | 2016-08-24 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的吡唑氨基嘧啶衍生物 |
| EA025186B1 (ru) * | 2012-06-29 | 2016-11-30 | Пфайзер Инк. | НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2 |
| RU2016134751A (ru) | 2014-01-29 | 2018-03-02 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
| SG11201605342UA (en) | 2014-01-29 | 2016-08-30 | Glaxosmithkline Ip Dev Ltd | Compounds |
-
2015
- 2015-01-28 SG SG11201605342UA patent/SG11201605342UA/en unknown
- 2015-01-28 US US15/114,858 patent/US10087186B2/en not_active Expired - Fee Related
- 2015-01-28 AU AU2015210593A patent/AU2015210593A1/en not_active Abandoned
- 2015-01-28 PE PE2016001250A patent/PE20161443A1/es unknown
- 2015-01-28 EP EP15743797.1A patent/EP3099695B1/en active Active
- 2015-01-28 MA MA39219A patent/MA39219B1/fr unknown
- 2015-01-28 EA EA201691514A patent/EA029774B1/ru not_active IP Right Cessation
- 2015-01-28 CA CA2937431A patent/CA2937431A1/en not_active Abandoned
- 2015-01-28 MX MX2016009893A patent/MX367370B/es active IP Right Grant
- 2015-01-28 UA UAA201609099A patent/UA118369C2/uk unknown
- 2015-01-28 JP JP2016549028A patent/JP6422986B2/ja not_active Expired - Fee Related
- 2015-01-28 WO PCT/CN2015/000055 patent/WO2015113452A1/en not_active Ceased
- 2015-01-28 CN CN201580006361.XA patent/CN105940004B/zh not_active Expired - Fee Related
- 2015-01-28 KR KR1020167020367A patent/KR20160106622A/ko not_active Ceased
- 2015-01-28 ES ES15743797T patent/ES2802174T3/es active Active
- 2015-01-28 CR CR20160348A patent/CR20160348A/es unknown
-
2016
- 2016-06-30 PH PH12016501307A patent/PH12016501307A1/en unknown
- 2016-07-03 IL IL246579A patent/IL246579B/en not_active IP Right Cessation
- 2016-07-26 CL CL2016001895A patent/CL2016001895A1/es unknown
- 2016-07-29 DO DO2016000195A patent/DOP2016000195A/es unknown
-
2018
- 2018-01-12 AU AU2018200277A patent/AU2018200277B2/en not_active Ceased
- 2018-08-02 US US16/052,791 patent/US10618901B2/en not_active Expired - Fee Related
-
2019
- 2019-01-15 DO DO2019000010A patent/DOP2019000010A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10618901B2 (en) | LRRK2 inhibitors for the treatment of Parkinson's disease | |
| JP6746679B2 (ja) | 化合物 | |
| CN110891954A (zh) | 富含亮氨酸的重复激酶2的抑制剂 | |
| US10858367B2 (en) | Compounds | |
| KR20150036020A (ko) | 피리미디닐 티로신 키나아제 억제제 | |
| CN110402247A (zh) | 化合物 | |
| JP2020506966A (ja) | 化合物 | |
| HK1230172B (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180322 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180921 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180920 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181017 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6422986 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |